Those players are exosomes: nanoscale vesicles, typically measuring between 30 and 150 nanometers, that are released by virtually all cell types, including tumor cells and stromal cells within the tumor microenvironment. Far from being cellular debris, exosomes are carefully constructed packages. They carry a cargo of proteins, lipids, and nucleic acids — including noncoding RNAs — that reflect the physiological state of the cell that produced them. When these vesicles fuse with recipient cells, they deliver their payload and can reprogram the target cell’s behavior. The review, led by Xingyao Li and Qiang Zhang of Tianjin University of Traditional Chinese Medicine together with colleagues at the National University of Singapore and Chengdu University of Traditional Chinese Medicine, synthesizes mechanistic evidence that positions exosomes as mobile signaling hubs capable of propagating immune suppression throughout tumor–immune networks.

The first and perhaps best-characterized resistance mechanism involves exosomal PD-L1, the same checkpoint molecule targeted by blockbuster immunotherapy drugs. Tumor cells shed exosomes bearing PD-L1 on their surface, and these vesicles act as molecular decoys. Therapeutic antibodies designed to block PD-L1 on tumor cells can be sequestered by exosomal copies of the protein, effectively diluting the drug and bypassing the checkpoint blockade altogether. At the same time, exosomal PD-L1 can directly engage PD-1 receptors on T cells, delivering inhibitory signals that blunt antitumor immune activity even in the presence of treatment. This dual function — decoy and suppressor — means that exosomal PD-L1 can undermine immunotherapy through two distinct routes simultaneously.

Beyond checkpoint interference, the review catalogs several additional circuits through which exosomes erode immunotherapy efficacy. One involves the induction of effector T-cell exhaustion and apoptosis. Exosome cargo, including specific microRNAs and other noncoding RNAs, can push cytotoxic T cells toward a dysfunctional, exhausted state characterized by impaired killing capacity, or can trigger programmed cell death in the very immune cells that immunotherapy is meant to activate. Another mechanism targets antigen presentation: exosomes can interfere with the machinery by which tumor cells display fragments of abnormal proteins on their surface, the molecular flags that T cells use to recognize cancer. When antigen presentation is suppressed, even a robustly activated T cell population has nothing to find and attack.

The fourth major circuit described in the review involves the amplification of immunosuppressive niches within the tumor microenvironment. Exosomes released under conditions of cellular stress can recruit and activate regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages — cell populations that collectively enforce an immune-permissive, tumor-friendly environment. Through diverse signaling pathways, these vesicles help convert the tumor microenvironment from a battlefield into a sanctuary, insulating cancer cells from immune attack and rendering checkpoint inhibitors far less effective than they would otherwise be.

Perhaps the most conceptually provocative idea in the review is that cellular stress can reprogram exosome biogenesis and cargo selection. Tumor cells exposed to hypoxia, nutrient deprivation, chemotherapy, or immunotherapy pressure itself do not simply produce more exosomes; they change what those exosomes contain. This adaptive repackaging enables the horizontal transfer of resistance phenotypes between cells — a resistant tumor cell can, in effect, share its survival strategies with neighboring cells that have not yet acquired them. The authors frame this as a driver of evolution toward immune escape, suggesting that exosome-mediated communication functions as a systems-level resistance platform that bridges tumor-intrinsic genetic alterations and microenvironmental adaptation.

This framing has significant implications for how resistance should be understood and measured. If resistance is not solely a property of individual tumor cells but an emergent property of a communicating network, then single-cell genetic sequencing of tumor biopsies may capture only part of the story. Exosomes circulating in a patient’s blood could, in principle, serve as liquid biopsy markers of emerging resistance, offering a real-time window into the evolving immunosuppressive state of the tumor microenvironment without repeated invasive procedures. The review’s synthesis suggests that monitoring exosomal cargo — particularly exosomal PD-L1 and resistance-associated noncoding RNAs — could complement existing biomarkers used to predict and track immunotherapy response.

Crucially, the review does not stop at diagnosis; it argues that exosomes are therapeutically targetable. Three intervention points emerge from the mechanistic analysis. The first is to inhibit exosome production or release itself, reducing the overall flux of immunosuppressive vesicles shed by tumor and stromal cells. The second is to neutralize specific cargo functions — for example, by blocking the interaction between exosomal PD-L1 and T-cell PD-1, or by depleting exosomes carrying resistance-conferring RNAs from circulation. The third is to disrupt vesicle-mediated signaling more broadly, preventing exosomes from fusing with and reprogramming recipient immune cells. Each strategy aims at the same goal: restoring the responsiveness of tumors to checkpoint blockade by dismantling the vesicle-based communication network that sustains resistance.

The therapeutic angle is especially timely because it opens the possibility of rational combination regimens. If exosome-driven mechanisms contribute to both primary and acquired resistance, then pairing checkpoint inhibitors with exosome-targeting agents could prevent resistance from emerging in the first place or reverse it once established. The review’s authors, whose work was supported by China’s National Key Research and Development Program and Singapore’s National Medical Research Council, position exosome targeting not as a replacement for immunotherapy but as a complementary strategy that addresses a resistance axis conventional approaches have largely ignored.

There remain substantial hurdles between mechanistic insight and clinical practice. Exosomes are heterogeneous, their cargo varies by tumor type and stage, and selectively targeting pathological vesicles without disturbing the physiological exosome traffic that normal cells depend on is a formidable challenge. Standardized methods for isolating and characterizing exosomes are still evolving, complicating both biomarker development and drug development. Nevertheless, the review’s central message is clear and consequential: exosome-mediated communication may constitute a systems-level platform through which tumors orchestrate immune escape, and understanding this platform — its circuits, its adaptive reprogramming under stress, and its vulnerabilities — may prove essential to converting immunotherapy’s partial successes into durable cures for the many patients in whom current treatments still fail.

Subject of Research: Exosome-mediated mechanisms of resistance to cancer immunotherapy

Article Title: Exosomes and cancer immunotherapy resistance: mechanistic circuits, adaptive reprogramming, and therapeutic targetability

Article References: Li, X., Zhang, Q., Wang, J., Zhao, J., Cao, S., Qiu, F., Zhou, J., Dong, X., Wong, A. L.-A., Wang, L., Shen, C., Kang, N., & Goh, B.-C. (2026). Exosomes and cancer immunotherapy resistance: mechanistic circuits, adaptive reprogramming, and therapeutic targetability. Molecular Cancer. https://doi.org/10.1186/s12943-026-02791-7

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02791-7

Keywords: exosomes, cancer immunotherapy, immune checkpoint blockade, PD-L1, tumor microenvironment, immunotherapy resistance, noncoding RNAs, T-cell exhaustion, antigen presentation, liquid biopsy, cancer biology, therapeutic targets

The study took a two-pronged approach. The investigators first examined an institutional cohort of 30 patients with BO-MBC, defined as synchronous or metachronous brain metastases in the complete absence of extracranial metastatic disease, treated between January 2017 and July 2024. They then turned to the National Cancer Database, a hospital-based registry jointly sponsored by the American College of Surgeons and the American Cancer Society that captures roughly 70 percent of newly diagnosed malignancies in the United States. From more than 1,500 accredited facilities, they identified 8,909 patients with metastatic breast cancer and synchronous brain metastases diagnosed between 2010 and 2020. Of these, 1,540 patients, or 17.3 percent, had brain-only disease, while the remaining 82.7 percent had brain metastases accompanied by concurrent extracranial metastases.

The clinicopathologic fingerprints of the two groups differed in striking ways. Patients with brain-only disease were more likely to have node-negative primary tumors, with 28.5 percent clinically node-negative at diagnosis compared with 20.1 percent of those with concurrent extracranial disease. They were also more likely to carry triple-negative tumors, at 26.0 percent versus 17.7 percent, and less likely to have hormone receptor-positive, HER2-negative disease, at 22.2 percent versus 31.3 percent. These differences were highly statistically significant and directionally consistent with earlier, smaller series suggesting that brain-only metastasis is enriched for aggressive, CNS-tropic tumor biology, particularly triple-negative and HER2-positive subtypes.

Treatment patterns diverged as well, and in a way that reveals how clinical decision-making is shaped by disease distribution. Patients with brain-only metastases were more likely to receive brain radiotherapy, at 54.8 percent versus 41.0 percent, yet paradoxically less likely to receive systemic therapy, at 67.2 percent versus 74.5 percent. The authors interpret this as a lingering reflex: when no overt disease exists outside the skull, clinicians have historically leaned on locoregional, CNS-directed treatment. Yet the survival analyses suggest this instinct may be due for revision, because systemic therapy was associated with the largest survival benefit precisely in the brain-only group.

Using overlap propensity score weighting, a statistical technique that reweights observational cohorts to mimic the covariate balance of a randomized trial, the team adjusted for age, race, ethnicity, comorbidity burden, molecular subtype, and treatment receipt. In unadjusted Kaplan-Meier analyses, median overall survival was 12.5 months for brain-only patients versus 10.6 months for those with concurrent extracranial disease. After adjustment, the brain-only group retained a lower hazard of death whether or not they received brain radiotherapy, with adjusted hazard ratios of 0.67 and 0.69 respectively, while radiotherapy conferred no statistically significant survival difference among patients with concurrent extracranial metastases. Most strikingly, brain-only patients who received systemic therapy had the most favorable outcomes of any subgroup, with an adjusted hazard ratio of 0.22 compared with extracranial-disease patients who received no systemic therapy.

The institutional cohort added granularity that national registries cannot provide, and it told a sobering story about where this disease actually fails. At a median follow-up of 26.5 months, median overall survival had not been reached, with one- and two-year survival rates of 97 and 90 percent. Median extracranial progression-free survival was 30.4 months, reflecting durable control of disease outside the brain. But median intracranial progression-free survival was only 14.6 months, and intracranial progression, whether parenchymal growth or the development of leptomeningeal disease, occurred in two-thirds of patients. Six patients, one-fifth of the cohort, eventually developed leptomeningeal disease, the diffuse seeding of the membranes surrounding the brain that remains one of the most feared complications in neuro-oncology.

That asymmetry, a body held in check while the brain progresses, is the biological heart of the paper. The central nervous system is a sanctuary site where the blood-brain barrier limits drug penetration, and the study documents how receptor biology can shift inside that sanctuary. Among 25 institutional patients who underwent neurosurgical resection, receptor discordance between the primary breast tumor and the brain metastasis was observed in 28 percent of cases, and every discordant event involved hormone receptor status, with no HER2 discordance. Three patients converted from hormone receptor-positive to hormone receptor-negative disease in the brain, and two converted in the opposite direction. Such conversions can silently invalidate a systemic regimen that was chosen based on the original tumor’s profile.

The radiation therapy findings demand careful reading. Within the brain-only group, patients treated with stereotactic radiosurgery or stereotactic radiotherapy showed better overall survival than those treated with whole brain radiation, with an adjusted hazard ratio of 0.76, and a similar association appeared in the extracranial-disease group. But the authors are emphatic that this should not be read as proof of modality superiority. Randomized trials comparing the two approaches have never shown a consistent survival advantage for stereotactic techniques; their established benefit lies in preserving neurocognitive function. Patients selected for radiosurgery in routine practice tend to have lower intracranial burden, better performance status, and more favorable prognoses, and the National Cancer Database does not capture tumor number, volume, location, symptoms, or salvage treatments, all of which drive modality selection. The survival signal almost certainly reflects selection bias rather than a direct treatment effect.

What the radiation data do support is a strategic argument. Because brain-only patients often live long enough for intracranial control and the late effects of CNS-directed therapy to dominate their quality of life, minimizing neurotoxicity becomes paramount. Neurocognitive-sparing stereotactic strategies, integrated with rigorous CNS surveillance and contemporary systemic therapy, may represent the optimal multidisciplinary framework for appropriately selected patients, even when the survival statistics alone cannot settle the question.

The study’s context is also a story about a therapeutic landscape in motion. Most patients in the national cohort were diagnosed before the widespread adoption of CNS-penetrant systemic agents, meaning the observed survival benefit of systemic therapy likely understates what is achievable today. In HER2-positive disease, the HER2CLIMB trial showed that adding tucatinib to trastuzumab and capecitabine produced a 47.3 percent intracranial response rate in patients with active brain metastases, while the antibody-drug conjugate trastuzumab deruxtecan achieved intracranial response rates of 73.3 percent in the phase II TUXEDO-1 trial and 62.3 percent overall in the phase 3b/4 DESTINY-Breast12 study, rising to 82.6 percent in previously untreated brain metastases. The CDK4/6 inhibitor abemaciclib has demonstrated blood-brain barrier penetration in hormone receptor-positive disease, and sacituzumab govitecan has shown emerging CNS activity in triple-negative breast cancer. As these agents increasingly control disease on both sides of the blood-brain barrier, the distinctions the study documents, between brain-only and widespread metastatic disease, between intracranial and extracranial failure, and between treatment effects that depend on disease distribution, will only grow more clinically consequential. The authors caution that registry limitations, including missing subtype data in roughly a quarter to a third of patients and the exclusion of metachronous brain metastases, mean these findings raise but do not establish the case for BO-MBC as a formal phenotype. What they establish beyond doubt is that the question now deserves prospective investigation in its own right.

Subject of Research: Brain-only metastatic breast cancer as a distinct clinical phenotype and its implications for radiation therapy and systemic treatment

Article Title: Brain-only metastatic breast cancer as a distinct clinical entity: evidence from national and institutional cohorts with implications for radiation therapy

Article References: Harrell, M., Kutuk, T., Gokun, Y., Upadhyay, R., Jhawar, S. R., Stover, D., Williams, N., Gatti-Mayes, M. E., Sizemore, G., LeFebvre, H., Grecula, J. C., Raval, R. R., Singh, R., Zhu, S., Blakaj, D. M., Chakravarti, A., Palmer, J. D., & Beyer, S. J. (2026). Brain-only metastatic breast cancer as a distinct clinical entity: evidence from national and institutional cohorts with implications for radiation therapy. Breast Cancer Research and Treatment, 219(3), Article 29. https://doi.org/10.1007/s10549-026-08092-3

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08092-3

Keywords: breast cancer, brain metastases, brain-only metastatic breast cancer, stereotactic radiosurgery, whole brain radiotherapy, National Cancer Database, triple-negative breast cancer, leptomeningeal disease, systemic therapy, radiation oncology, intracranial progression, CNS-penetrant therapies

The original article, published on 7 August 2019, reported that NR1B2, a member of the nuclear receptor family, appeared to restrain the growth and spread of kidney renal clear cell carcinoma cells. According to the study, manipulating the expression of this gene influenced the migratory and invasive behaviour of cancer cells in laboratory models, and the authors linked these effects to regulation of the Hippo pathway effector YAP, a transcriptional co-activator with well-established roles in organ size control, tissue regeneration and tumour progression. Findings of this kind attract attention because clear cell renal cell carcinoma frequently metastasises and often develops resistance to existing therapies, making any apparent tumour-suppressive pathway a potential lead for drug development.

The concerns that ultimately ended the paper’s life centred on its figures. According to the retraction note, several panels in the study appeared to contain overlapping or duplicated image regions, a category of irregularity that image-integrity specialists and journal editors treat as a serious red flag. In Figure 3I, the upper left section of the PLKO/Migration panel and the lower right section of the PLKO/Invasion panel appeared to overlap. In Figure 5B, the 786-O SH-NR1B2 band of NR1B2 and the SW839 OE-NR1B2 band of P-YAP appeared to overlap when one of them was flipped. These are the kinds of discrepancies that are difficult to explain as innocent technical artefacts, because they suggest that the same underlying image data may have been used to represent different experimental conditions.

Further irregularities spanned multiple figures. The retraction note states that the OE-NR1B2/Invasion and PWPI/Migration panels of Figure 3H appeared to overlap with the OE-NR1B2(+) Si-YAP(-)/Invasion and OE-NR1B2(-) Si-YAP(-)/Migration panels of Figure 5G, respectively. In practical terms, this means that images presented as evidence for distinct experimental comparisons, in different figures of the paper, appeared to derive from the same source material. Migration and invasion assays are foundational experiments in cancer biology: they measure how cancer cells move through membranes or matrices, and their results are used to argue that a gene promotes or suppresses metastatic behaviour. If the images underpinning those assays are duplicated or rearranged, the central claims of the paper lose their evidentiary foundation.

When the concerns were raised, the authors were given an opportunity to respond. According to the retraction note, they provided some source data on request from the Publisher, but this material was judged insufficient to address the issues that had been identified. In the world of research integrity, source data, the raw image files, numerical readouts and laboratory records behind a published figure, is the ultimate arbiter. If original files can be produced and they match the published figures and the described experiments, concerns can often be resolved. When the supplied material falls short, editors are left with published images that show apparent duplication and no adequate explanation, and the standard response is retraction.

Compounding the problem, none of the authors responded to any correspondence from the Publisher regarding the retraction. Silence at this stage is significant. Retraction is not supposed to be a punishment imposed without due process; journals typically notify authors, invite comment, and consider any evidence offered before acting. When authors do not engage, editors must make a decision based on the available record. In this case, the combination of multiple overlapping figure panels, incomplete source data and non-response left the Editor-in-Chief with little alternative but to withdraw the paper from the literature.

The retraction carries technical implications for researchers who work on renal cell carcinoma and on the NR1B2 gene. NR1B2, also known in the literature as a retinoic acid receptor-related orphan receptor family member, belongs to a class of ligand-activated transcription factors that regulate gene expression programs involved in metabolism, differentiation and cell growth. Because nuclear receptors are druggable proteins, studies implicating them in cancer suppression often spark interest in pharmacological modulation. The retracted paper’s claim that NR1B2 restrains clear cell renal cell carcinoma progression by regulating YAP signalling would, if validated, have pointed toward a specific signalling axis that could be targeted. Researchers citing the paper will now need to treat its conclusions as unsupported, and any lines of investigation built on its figures will require independent re-examination.

The case also illustrates how the Hippo-YAP pathway became a crowded and competitive area of cancer research, and how that intensity can create pressure that sometimes manifests in the literature as image problems. YAP and its paralog TAZ act as sensors of mechanical and developmental cues, driving expression of genes that promote proliferation and block apoptosis. In many tumour types, including renal cancer, elevated YAP activity is associated with aggressive disease. Demonstrating that an upstream nuclear receptor suppresses YAP would be a coherent and attractive mechanistic story, which is precisely why such a result, once published in an open-access cancer research journal, would be picked up by other groups. The retraction means that this particular story must now be regarded as unproven rather than disproven, but the distinction matters little for scientists deciding whether to invest time and grant money in following it up.

For the broader scientific community, the episode is another data point in the ongoing effort to police the integrity of the biomedical literature. Journals increasingly use automated and manual image forensics to detect duplicated panels, spliced gels and mirrored blots, and readers increasingly report suspicious figures through channels such as PubPeer. Retraction notes like this one, which itemise the specific concerns in detail, serve a dual purpose: they warn researchers away from relying on the retracted findings, and they document the evidentiary basis for the withdrawal so that the decision itself can be scrutinised. The detailed listing of the overlapping panels in Figures 3H, 3I, 5B and 5G in this retraction note follows that transparent convention.

The original article remains accessible online, as is standard practice, but it is now watermarked with the retraction so that readers encountering it are alerted to its status. The retraction note itself, published as Volume 45, article number 209 of the Journal of Experimental & Clinical Cancer Research, was released on 7 October 2026, more than seven years after the original publication. For patients and clinicians, the practical consequences are limited: no therapy was developed from this paper in the intervening years. For the research record, however, the correction is meaningful. Science advances not only through new discoveries but through the careful removal of results that can no longer be trusted, and this retraction, however late, ensures that the claim that NR1B2 suppresses kidney renal clear cell carcinoma progression will no longer circulate as established fact.

Subject of Research: Retraction of a study on NR1B2 regulation of kidney renal clear cell carcinoma progression

Article Title: Retraction Note: NR1B2 suppress kidney renal clear cell carcinoma (KIRC) progression by regulation

Article References: Yin, L., Li, W., Wang, G., Shi, H., Wang, K., Yang, H., & Peng, B. (2026). Retraction Note: NR1B2 suppress kidney renal clear cell carcinoma (KIRC) progression by regulation. Journal of Experimental & Clinical Cancer Research, 45(1), Article 209. https://doi.org/10.1186/s13046-026-03839-8

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03839-8

Keywords: retraction, kidney cancer, renal cell carcinoma, NR1B2, YAP signalling, research integrity, image duplication, tumour suppressor, cancer biology, Journal of Experimental & Clinical Cancer Research, figure manipulation, Hippo pathway

The structural logic of MUC1 explains both its normal function and its malignant potential. The MUC1 gene, located on chromosome 1q21-24, encodes a single polypeptide of 120 to 225 kilodaltons that balloons to 250 to 500 kilodalts after glycosylation. Its extracellular region contains between 20 and more than 100 tandem repeats of a 20-amino-acid sequence, each repeat carrying five O-glycosylation sites, producing a glycocalyx that extends hundreds of nanometers beyond the cell surface. Critically, the protein undergoes autoproteolysis within its SEA domain, cleaving at a GSVVV motif into two subunits that remain associated as a non-covalent heterodimer: MUC1-N, the sheddable, sugar-laden protective arm, and MUC1-C, a compact transmembrane unit with a 58-amino-acid extracellular domain, a 28-amino-acid membrane anchor, and a 72-amino-acid cytoplasmic tail that functions as the molecule’s oncogenic brain. In normal epithelia, the complex sits strictly at the apical membrane; in tumors, it spreads across the entire cell surface and into the cytoplasm, its O-glycans truncated into tumor-associated forms such as Tn, sTn, TF, and sTF.

MUC1-C is where the real molecular action happens. Its extracellular domain carries an NLT motif whose N-glycans recruit galectin-3, which in turn bridges MUC1-C to EGFR and other receptor tyrosine kinases at the membrane. Its cytoplasmic tail bristles with 12 documented and putative phosphorylation sites that serve as substrates for EGFR, Src-family kinases, ABL, GSK3β, and ZAP70, creating docking platforms for effectors such as PI3K, SRC, and GRB2. A CQC motif near the membrane, activated by reactive oxygen species, drives MUC1-C oligomerization and directs the protein to the nucleus via importin-β and to mitochondria via HSP70/90 chaperones, where it blocks the intrinsic apoptotic pathway. In the nucleus, MUC1-C binds β-catenin and TCF4 to occupy the CCND1 promoter, recruits p300 to acetylate histone H3K27, and interacts directly with p53, IKKα, IKKβ, and RelA, placing it at the command posts of the Wnt, p53, and NF-κB pathways simultaneously.

Two auto-inductive feedback loops give this signaling web its self-sustaining, pathological persistence. MUC1-C binds JAK1 and STAT3 directly, promoting STAT3 phosphorylation; activated STAT3 then binds the MUC1 promoter, cranking out more MUC1-C in a loop that is transient during normal inflammatory responses but constitutively locked on in carcinomas. A parallel loop operates with NF-κB, which MUC1-C activates both by stimulating the IKK complex and by physically blocking NF-κB’s inhibitor IκBα. Beyond these canonical circuits, the review highlights MUC1-C’s emerging role as an epigenetic master regulator: the protein induces the Yamanaka pluripotency factors OCT4, SOX2, KLF4, and MYC, binds the Polycomb marks H2A K119 ubiquitylation and H3K27 methylation, and reshapes chromatin accessibility at JUN/AP-1-regulated enhancers, thereby enforcing the lineage plasticity and stem-like state that make cancer cells so hard to eradicate.

The downstream consequences for anti-tumor immunity are stark. MUC1-C’s cytoplasmic tail sustains a JAK1-STAT1-IRF1 transcriptional axis that upregulates IDO1 and COX2/PTGES, depleting tryptophan, accumulating kynurenine, and generating prostaglandin E2, together halting CD8-positive T-cell cycling and pushing regulatory T-cell differentiation. MUC1-C also delivers mutant p53 and β-catenin to the CTGF promoter, unleashing connective tissue growth factor that recruits cancer-associated fibroblasts and deposits a physical collagen barrier. Analyses of TCGA, METABRIC, and single-cell datasets consistently show that MUC1-high tumors are depleted of cytotoxic T cells, Th1 helpers, B cells, and M1 macrophages while enriched in Tregs, myeloid-derived suppressor cells, and M2-polarized tumor-associated macrophages. Even at the glycan level, sTn-decorated MUC1 engages Siglec-9 on myeloid cells to trigger a calcium-MEK-ERK program that completes macrophage polarization and renders tumors refractory to PD-1 blockade, effectively converting an immunological hotbed into what the authors describe as an ice cave.

Disease-specific evidence reinforces the breadth of this mechanism. In breast cancer, high MUC1 mRNA predicts reduced overall, disease-free, and recurrence-free survival; MUC1-C interacts with estrogen receptor alpha to drive tamoxifen resistance, forms a self-sustaining loop with TWIST1 that underlies paclitaxel resistance, and cooperates with STAT1 in roughly 15 percent of primary breast tumors, a co-expression pattern linked to poor outcomes. In non-small cell lung cancer, MUC1-C drives acquired resistance to osimertinib by sustaining ERK and AKT signaling through EGFR/MET heterodimerization, occupies the CD274 promoter to induce PD-L1, and represses immune genes such as TLR9 and IFN-γ through ZEB1. In pancreatic ductal adenocarcinoma, where MUC1 is overexpressed in more than 60 percent of cases, the protein stabilizes HIF-1α, accelerates glycolysis and pyrimidine biosynthesis, and accumulates endogenous dCTP that directly antagonizes gemcitabine, while also suppressing BRCA1 and blunting radiosensitivity.

The oncogenic reach extends into blood cancers and chronic inflammatory disease. MUC1 is overexpressed specifically in acute myeloid leukemia stem cells, where it stabilizes both wild-type and mutant FLT3 receptors and activates the AKT/ERK/STAT5 axis; the peptide inhibitor GO-203 selectively eliminates these stem cells while sparing normal hematopoiesis. In chronic myeloid leukemia, MUC1 physically stabilizes the Bcr-Abl fusion protein and maintains imatinib resistance, while in multiple myeloma, aberrantly glycosylated MUC1 appears on 73 percent of malignant plasma cells and drives the WNT/β-catenin-TCF4-MYC survival program alongside redox balance maintained with TIGAR. Outside oncology, loss of MUC1 in chronic obstructive pulmonary disease correlates with steroid resistance, aberrant MUC1 glycosylation in ulcerative colitis promotes colitis-associated colorectal cancer, and frameshift mutations in the VNTR region cause autosomal dominant tubulointerstitial kidney disease through endoplasmic reticulum stress.

Therapeutically, the field has learned hard lessons but is now fielding a far more sophisticated arsenal. Only two MUC1-targeted drugs have reached phase III trials, the liposomal peptide vaccine Tecemotide and the poxviral vector TG4010, and both failed to improve survival, a result attributed in part to MUC1’s poor intrinsic immunogenicity and the redundancy of the pathways it controls. The current generation of approaches is more precise: monoclonal antibodies such as DMB5F3 against the SEA domain and GGSK-1/30, whose zirconium-89-labeled form achieved over 50 percent injected dose per gram tumor uptake with 96.5 percent diagnostic specificity in PET imaging; antibody-drug conjugates including 3D1-MMAE, which eradicated MUC1-positive lung and breast tumors in transgenic mice without toxicity; CAR-T cells engineered against the tumor-specific Tn-glycoform of MUC1, which spare normal epithelium; armored allogeneic CAR constructs with PD1 and TGFBR2 knockout and IL-12 insertion; oncolytic adenoviruses encoding MUC1-CD3 bispecific T-cell engagers; and RNA interference delivered by MUC1-aptamer-tethered nanoparticles.

The review’s authors are candid about the remaining obstacles. Because MUC1-C sits at the hub of so many compensatory networks, single-agent inhibition invites bypass signaling through AXL, MET, or downstream PI3K and MEK pathways, and chronic blockade can push cells toward stem-like or neuroendocrine phenotypes through epigenetic remodeling. The most promising path, they argue, is rational combination and sequencing: pairing MUC1-C inhibitors with PI3K/AKT/mTOR blockade, PD-1 antibodies, or epigenetic drugs such as decitabine, or using MUC1-C inhibition as a priming step to reverse epithelial-mesenchymal transition before conventional chemotherapy or checkpoint inhibitors. Preclinical combination studies already show dramatic gains, with a MUC1-MBP vaccine plus anti-PD-1 raising tumor clearance in mice from 20 to 80 percent. With nanodelivery systems, cell-carrier platforms, and MUC1-triggered smart materials now entering the design space, the molecule once dismissed after two failed phase III trials is being repositioned as what may become one of oncology’s most consequential pan-cancer targets, provided that mechanistic depth and rigorous clinical validation keep pace with the enthusiasm.

Subject of Research: The role of the MUC1 mucin, particularly its MUC1-C subunit, in oncogenic signaling, immune evasion, and targeted cancer therapy development

Article Title: MUC1 in cancer

Article References: Qian, K., Zhang, Y., Zhou, Q., Zhou, J., Wu, X., Zhu, J., Pan, Y., Wu, Z., Li, S., Lin, Y., Lyu, F., Chen, S., & Sun, H. (2026). MUC1 in cancer. Holistic Integrative Oncology, 5(1), Article 32. https://doi.org/10.1007/s44178-026-00257-w

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00257-w

Keywords: MUC1, MUC1-C, cancer biology, oncogenic signaling, immune evasion, immunotherapy, CAR-T cells, antibody-drug conjugates, cancer vaccines, drug resistance, epigenetic reprogramming, tumor microenvironment

The study, published in Scientific Reports, was led by Professor Tamiki Komatsuzaki of Hokkaido University and focused on one of biology’s classic model organisms: the soil-dwelling amoeba Dictyostelium discoideum. This single-celled organism has long fascinated scientists because of what it does when food runs out. When bacteria are scarce and starvation sets in, the amoebas begin releasing a chemical signal called cyclic AMP, or cAMP. Neighboring cells detect the signal, respond by releasing more of it, and begin crawling toward its source. The result is a spreading chemical wave that sweeps across the colony, and the cells ride that wave toward one another, eventually assembling into a multicellular organism. This dramatic transformation helps the amoebas survive hostile conditions, and it recapitulates, in miniature, the kind of collective cell behavior that underlies development, immunity, and disease in animals.

For decades, researchers studying this aggregation process have faced a practical dilemma. One approach is to track individual cells, following each amoeba’s path frame by frame to see how it moves. That works reasonably well when cells are sparse, but it becomes nearly impossible once the cells crowd together during aggregation, when one cell’s trail blurs into its neighbor’s. A second approach is to measure the cAMP wave itself, determining the direction in which the chemical signal is traveling across the colony. But these two measurements have traditionally been carried out separately, leaving a crucial gap: no direct, simultaneous view of how the wave’s dynamics relate to what each individual cell is actually doing at that instant. “How individual cells read passing waves of chemical signals and translate them into coordinated group migration has been hard to pin down,” Komatsuzaki explained.

The new study closes that gap with an ingenious imaging strategy. The team used fluorescent microscopy to record both cell movement and cAMP levels at the same time, frame by frame, throughout the aggregation process. Then came the clever part. The researchers took their sharp images and deliberately blurred them by different amounts, creating a series of versions of the same footage at different spatial scales. To each blurred version, they applied a computational technique called particle image velocimetry, or PIV, a method originally developed in fluid dynamics to trace the flow of liquids and gases by tracking patterns of motion between successive frames.

The logic behind the multiscale blurring is elegant. In the sharpest images, the analysis picks out the trajectories of individual cells, revealing each amoeba’s personal path across the colony floor. But as the images are blurred more heavily, the small, jittery movements of individual cells average out, and what remains is the larger, smoother pattern of motion embedded in the colony as a whole — the signature of the cAMP wave itself. By analyzing the same footage at multiple scales simultaneously, the researchers could directly compare the dynamics of the chemical wave with the movements of individual cells throughout the entire experiment, without ever having to separate the cells physically or measure the wave by an independent method. The team describes the result as a multiscale Eulerian velocity vector field: a map of motion that captures both the fine-grained behavior of single cells and the coarse-grained behavior of the collective at every moment.

Armed with this technique, the researchers tracked the amoebas continuously from two to seventeen hours after the onset of starvation, covering the full arc of the aggregation process. What they saw was a strikingly consistent pattern of behavior. As a cAMP wave approaches a cell, the amoeba surges forward to meet it almost head-on, racing toward the incoming chemical signal. But when the wave crests and begins to recede, something unexpected happens: the cell does not reverse direction to chase the departing wave. Instead, its motion stays locked in the same direction it was already traveling, carrying it forward even as the signal moves away. Only after the wave has passed does the cell settle down, resting directionless in the trough of the wave until the next one arrives — at which point the entire cycle repeats.

Komatsuzaki offered a vivid analogy for this behavior. “It’s like watching a crowd of surfers paddle hard to catch a wave, ride it together, and then bob around waiting for the next one,” he said. The image is apt in more than spirit. Each amoeba behaves like a surfer who paddles furiously toward an incoming swell, gains momentum as the wave lifts, coasts in the same direction even after the wave has passed beneath, and then drifts idly until the next swell appears. No individual surfer needs to know where the shore is or what the other surfers are doing; the collective pattern emerges from each cell responding to the same passing wave at the same time.

The directional locking that the researchers observed is particularly significant for understanding the physics of chemotaxis, the process by which cells move toward chemical attractants. A naive expectation might be that a cell responding to a chemical gradient would simply follow the gradient, reversing course whenever the gradient reverses. The amoebas do something subtly different: their response to the wave is temporally asymmetric, with a strong forward surge during the rising phase of the wave and a persistence of motion during the falling phase. This asymmetry, repeated wave after wave across thousands of cells, is what allows the colony to funnel itself steadily inward toward the aggregation center. The large-scale cAMP waves, visualized in the team’s images as smooth ripples spreading across the colony, were found to move in a direction precisely opposite to the average direction of individual cell movement — a 180-degree reversal that becomes visible only when single-cell motion and wave motion are compared side by side.

According to the authors, the findings offer the first systematic map of how the amoebas’ collective behavior emerges from individual action. That map matters beyond the world of social amoebae. Because the imaging technique separates single-cell motion from collective motion in the same dataset, the team believes it could be applied to far more complex systems, including populations of mammalian cells. One tantalizing possibility is identifying which cells act as “leaders” — initiating and shaping the waves — and which act as “followers,” responding to signals generated by others. In immune responses, where swarming neutrophils and other cells coordinate their pursuit of pathogens, and in cancer biology, where collectively invading tumor cells move through tissue in coordinated groups, such leader-follower dynamics are thought to play a decisive role but are notoriously hard to disentangle.

The study also demonstrates the value of borrowing tools from other disciplines. Particle image velocimetry was developed to measure fluid flow in wind tunnels and rivers, not to watch amoebas crawl across a petri dish. By adapting it to multiscale biological imaging, the researchers have created a method that treats a cell colony like a flowing medium with structure at every scale — a perspective that may prove broadly useful for studying active matter, tissue mechanics, and developmental biology. For now, the work provides something biologists have long lacked: a direct, quantitative picture of the moment when solitary cells stop being solitary. In the starved amoeba’s simple act of paddling toward a chemical wave and riding it together with its neighbors lies a principle that echoes through wound healing, immune defense, and cancer spread — the principle that a crowd, given the right signal, can behave like a single living thing.

Subject of Research: Collective cell migration in Dictyostelium discoideum via cAMP chemotactic wave signaling

Article Title: Study reveals how individual cells ‘surf’ chemical waves to form a collective

Article References: Study reveals how individual cells ‘surf’ chemical waves to form a collective. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Dictyostelium discoideum, cAMP, chemotaxis, collective cell migration, particle image velocimetry, fluorescent imaging, Hokkaido University, multicellularity, cell signaling, immune response, cancer biology, Scientific Reports

The review, co-led by Dr. Dan Theodorescu of the University of Arizona Cancer Center and Dr. Dena B. Dubal of the University of California, San Francisco, synthesizes a growing body of evidence from human studies, mouse models, and advanced genomic technologies. The authors argue that the genes located on the sex chromosomes provide specific instructions that shape cellular function throughout an individual’s lifespan. These genetic signals operate both in isolation and in concert with hormonal pathways, creating a dual-layered system of biological regulation. By integrating these disparate findings, the study provides a unified framework for understanding how sex-specific biology influences major disease categories, including cancer, neurological conditions, and cardiometabolic disorders.

In female biology, the mechanism of X-chromosome inactivation is a central theme of the research. Although one of the two X chromosomes is largely silenced early in development to balance gene dosage with males, this process is not absolute. The review highlights that certain genes on the inactive X chromosome remain active, and others can re-activate with age. This phenomenon results in female cells possessing extra doses of specific genetic material compared to male cells. Furthermore, the origin of the active X chromosome appears to be biologically significant. Studies in mouse models indicate that whether the active X is inherited from the mother or the father can influence physiological outcomes. Mice whose cells predominantly relied on the maternal X chromosome exhibited accelerated brain aging and memory decline, suggesting that the parental origin of sex-linked genes has tangible effects on neurodegeneration and cognitive health.

The stability of sex chromosomes also declines with age, a process that has profound implications for disease susceptibility. The review details how cells can lose an entire sex chromosome over time, a phenomenon known as aneuploidy. In women, the loss of an X chromosome is specifically linked to an increased risk of leukemia, although the broader systemic effects of this loss are still being characterized. In men, the loss of the Y chromosome, which is most commonly measured in circulating blood cells, is associated with a wide array of age-related pathologies. These include various cancers, cardiovascular disease, severe infections, and Alzheimer’s disease. The loss of these chromosomes is increasingly being explored not just as a consequence of aging, but as a potential biomarker and even a causal contributor to the development of chronic diseases.

The implications for oncology are particularly striking, as the research provides a mechanistic explanation for sex-based differences in cancer outcomes. Dr. Theodorescu’s laboratory has previously demonstrated that tumors which lose the Y chromosome gain the ability to evade the immune system. This immune evasion provides a biological rationale for why the loss of the Y chromosome has been statistically linked to increased mortality from carcinomas in men. However, the review also notes a paradoxical therapeutic advantage: tumors that have lost the Y chromosome may respond more favorably to immunotherapy. Understanding this complex interplay between chromosomal loss and immune surveillance could allow clinicians to tailor treatment strategies based on the specific genetic profile of a patient’s tumor, moving toward a more personalized approach to cancer care.

Beyond cancer, the review underscores the role of sex chromosomes in cardiovascular and metabolic health. The genetic instructions on the X and Y chromosomes influence how the heart and metabolic systems respond to stress and aging. By identifying these non-hormonal pathways, the study suggests that current diagnostic tools and treatment protocols may be overlooking critical variables. For instance, the differential expression of X-linked genes in heart tissue could explain why men and women present with and respond to heart disease in distinct ways. Integrating sex-chromosome analysis into cardiometabolic research could lead to the development of targeted therapies that address the root genetic causes of these conditions, rather than merely managing their symptoms.

The origins of this comprehensive review can be traced to discussions at the 2025 National Institute on Aging Workshop, which focused on sex differences impacting human health across the lifespan. The collaboration between researchers from the University of Arizona, UC San Francisco, Northwestern University, and other institutions reflects a broader scientific movement toward recognizing sex as a biological variable in all areas of medical research. The authors emphasize that this work is intended to stimulate further investigation and raise awareness of the significant potential of studying sex chromosomes in the context of disease. By highlighting the far-reaching diagnostic and therapeutic implications of this research, the review aims to bridge the gap between basic genetic science and clinical application.

The study also highlights the importance of designing clinical trials that are sex-aware. Historically, many clinical trials have treated men and women as a homogeneous group, often under-representing one sex or failing to analyze outcomes by sex. The review argues that when clinical trials are designed to account for these cellular differences, researchers can translate scientific findings into personalized medical care more effectively. This approach ensures that treatments and diagnostics are tailored to match every patient’s unique genetic profile, rather than relying on population averages that may mask critical sex-specific variations. Such a shift would enhance the precision of medicine and improve outcomes for both male and female patients.

Previous research from Dr. Theodorescu’s group has further illuminated the role of Y-chromosome loss in immune cells. The team found that the loss of the Y chromosome in T cells and cancer cells in men provides tumors with the ability to evade immune detection. This finding offers a concrete explanation for the observed link between Y-chromosome loss and increased mortality from carcinomas. Additionally, recent studies have shown that the loss of the Y chromosome in normal-appearing tissues can serve as an early warning sign of genetic instability. This loss may mark a hidden zone of risk where cancer is likely to develop, providing a potential window for early intervention and prevention. These findings collectively paint a picture of the Y chromosome as a critical regulator of genomic stability and immune function.

Ultimately, this review represents a significant step forward in understanding the biological basis of sex differences in health and disease. By demonstrating that the X and Y chromosomes are active participants in health and disease throughout a person’s life, the study challenges the traditional view of these chromosomes as mere determinants of sex. The research opens new avenues for exploring how sex-specific genetic mechanisms can be leveraged to improve diagnosis, treatment, and prevention of major diseases. As the field of sex-aware medicine continues to grow, the insights provided by this review will likely play a crucial role in shaping future research agendas and clinical practices, ensuring that the unique biology of both men and women is fully accounted for in the pursuit of better health outcomes.

Subject of Research: The role of X and Y chromosomes in determining disease risk, aging, and physiological health independent of hormonal influences.

Article Title: Study: Sex chromosomes drive how bodies deal with cancer, heart health and longevity

Article References: Study: Sex chromosomes drive how bodies deal with cancer, heart health and longevity. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: sex chromosomes, cancer biology, aging, genetics, cardiovascular health, immunology, precision medicine, X-chromosome inactivation, Y-chromosome loss, biomarkers, clinical trials, neurodegeneration

The problem the researchers set out to solve is known as cell-type deconvolution. Modern sequencing technologies allow scientists to profile gene expression in individual cells, building reference atlases that describe the molecular fingerprints of dozens of cell types. Bulk RNA sequencing, by contrast, measures the average expression of millions of cells at once, producing a single blended signal. Deconvolution methods attempt to reverse this blending, using single-cell references to estimate the proportions of each cell type in the mixed sample. The catch is that the reference data and the target data rarely come from the same world. Differences in tissue processing, sequencing platforms, donor populations, and even the fundamental physics of the measurement—counting RNA transcripts versus quantifying proteins—create distribution discrepancies that can quietly corrupt the estimates. Existing statistical and deep learning approaches, the authors note, are often undermined by exactly these cross-domain gaps.

CrossBranch attacks the problem with a dual-branch representation learning architecture, a design that processes the same data through two complementary channels before merging them. The first branch operates at the level of individual genes, capturing fine-grained expression patterns that distinguish one cell type from another. The second branch is pathway-informed, meaning it encodes the data through the lens of curated biological pathways—coordinated groups of genes that work together in processes such as immune signaling, metabolism, or cell division. By combining gene-level and pathway-level information, the framework aims to learn representations that are both precise and biologically meaningful, less likely to be thrown off by noise in any single gene and more likely to capture the coordinated programs that actually define cellular identity.

One of the most clever aspects of the method is how it sidesteps the chronic shortage of ground truth. In real tissues, nobody knows the exact proportions of every cell type, so there is nothing to train a supervised model on directly. CrossBranch solves this by generating labeled simulated mixtures from single-cell reference data. The software takes known single-cell profiles and artificially blends them in controlled proportions, producing training examples where the correct answer—the true cell-type composition—is known by construction. A prediction head, the final layer of the neural network, is then trained on these simulated mixtures to estimate cell-type proportions from mixed expression profiles.

But training on simulated data alone would recreate the very problem CrossBranch was designed to fix: the simulated mixtures would live in a slightly different statistical universe than the real target samples. The framework therefore adds a latent-space alignment strategy. Both the simulated mixtures and the real target data are encoded into a shared latent space, a compressed mathematical representation learned by the network, and the training process actively reduces the distribution discrepancies between them in that space. In effect, the model learns to view simulated and real data as if they came from the same domain, allowing knowledge gained from the labeled simulations to transfer accurately to real bulk RNA-seq, proteomic, and spatial measurements.

Spatial transcriptomics, a technology that measures gene expression while preserving the physical layout of a tissue slice, receives special treatment in the framework. Because neighboring spots on a spatial slide are likely to share similar cellular environments—cells do not arrange themselves randomly—CrossBranch incorporates a neighboring-spot-based spatial consistency loss. This additional term encourages the model to produce proportion estimates that vary smoothly across adjacent locations, suppressing implausible spatial flicker while still allowing genuine biological boundaries, such as the edge of a tumor nest, to show through. Ablation analyses, in which individual components of the model are removed one at a time, confirmed that the pathway-level representation, the cross-domain alignment, and the spatial neighborhood modeling each contribute measurably to the overall performance.

How well does it actually work? Across benchmark datasets spanning bulk RNA sequencing, proteomics, and spatial transcriptomics, CrossBranch consistently achieved competitive deconvolution performance compared with existing statistical and deep learning methods. That breadth matters. Most deconvolution tools are built for one modality and stumble when handed data from another, particularly proteomics, where the measured molecules are proteins rather than RNA transcripts and the correspondence between reference and target is even more tenuous. A single unified framework that performs well across all three modalities simplifies the analytical pipeline for research groups that routinely juggle multiple data types from the same patient samples.

The most striking results, however, come from the applications to cancer. The researchers applied CrossBranch to prostate, colorectal, and pancreatic tumor datasets, and the framework succeeded in identifying tumor-associated cellular changes—shifts in the cellular makeup of diseased tissue compared with healthy tissue—as well as cell-type patterns associated with patient survival. In the spatial analyses, CrossBranch pinpointed the localization of malignant epithelial cells within tissue sections, detected the co-localization of fibroblasts and endothelial cells, a pairing widely studied in tumor biology because cancer-associated fibroblasts and blood vessel cells cooperate to shape the tumor microenvironment, and revealed compartment-specific spatial organization within tumors. These are exactly the kinds of findings that turn a deconvolution tool from a mathematical curiosity into a biological instrument.

The significance of this work lies in what it says about the future of computational biology. Tissue heterogeneity is central to understanding disease mechanisms: a tumor that is 40 percent cancer-associated fibroblasts may respond very differently to immunotherapy than one dominated by cytotoxic T cells, even if the malignant cells themselves look identical. Tools like CrossBranch make it possible to extract that compositional information from the cheap, routine bulk measurements that hospitals already generate, rather than requiring expensive single-cell or spatial assays for every sample. By explicitly modeling the domain gap between reference and target data, the method addresses what many in the field consider the central weakness of deconvolution approaches, and the open availability of the source code on GitHub for academic and noncommercial use should accelerate adoption and independent testing.

There are, of course, the usual caveats that accompany any new machine learning method in biology. The framework depends on the quality and relevance of the single-cell reference atlases used to generate its simulated training mixtures, and performance on a given tissue will reflect how well those references capture the true cellular diversity of the sample. The published benchmarks and cancer applications are encouraging, but as with any computational tool, the broader community will need to stress-test it across additional tissues, diseases, and platforms. Still, the combination of pathway-informed representations, cross-domain alignment, and spatial consistency represents a thoughtful synthesis of biological knowledge and deep learning design. As spatial omics technologies mature and reference atlases grow, frameworks like CrossBranch point toward a future in which the cellular composition of any tissue—healthy or diseased—can be read out reliably from whatever measurement happens to be available, bringing the hidden mosaic of human tissue into sharper focus than ever before.

Subject of Research: Cross-domain cell-type deconvolution using dual-branch representation learning for omics data

Article Title: CrossBranch: cross-domain cell-type deconvolution with dual-branch representation learning

Article References: Yi, Q., Yuan, J., Xu, P., & Liu, W. (2026). CrossBranch: cross-domain cell-type deconvolution with dual-branch representation learning. BMC Genomics. https://doi.org/10.1186/s12864-026-13360-z

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13360-z

Keywords: cell-type deconvolution, cross-domain learning, representation learning, single-cell RNA sequencing, bulk RNA-seq, proteomics, spatial transcriptomics, tumor microenvironment, pathway-level representation, deep learning, cancer biology, BMC Genomics

The review, led by researchers at West China Hospital of Sichuan University, is notable for its insistence on rigor. The authors point out that while aberrant condensate behavior is increasingly implicated in cancer, many intracellular assemblies that have been attributed to LLPS have not been validated using strict experimental criteria. This matters because the cell contains many different ways of organizing matter: stable enzymatic complexes, scaffold-driven assemblies, polymer networks, and gel-like aggregates can all look like droplets under a microscope without being true liquid phases. A true LLPS droplet typically forms through weak, multivalent interactions among intrinsically disordered regions of proteins, fuses and relaxes like a liquid, exchanges components dynamically with the surrounding dilute phase, and dissolves predictably when conditions such as salt concentration, temperature, or protein concentration change. The review lays out an evidence-oriented framework for applying these criteria before labeling a structure a phase-separated condensate, a discipline the authors say the cancer field urgently needs.

At the biophysical level, condensate formation depends on a set of molecular determinants that the review examines in detail. Intrinsically disordered regions, or IDRs, are stretches of protein sequence that do not fold into a single rigid structure but instead sample many conformations. These regions carry distributed motifs—charged blocks, aromatic residues, proline-rich motifs, and arginine-glycine rich elements—that engage in multiple weak, transient interactions with one another. When the combined valence and strength of these interactions cross a threshold, the molecules demix into a dense phase enriched in those components and a dilute phase depleted of them. RNA, multivalent scaffolding proteins, and post-translational modifications such as phosphorylation, methylation, SUMOylation, and O-GlcNAcylation all tune where that threshold sits. The result is that a cell can, in principle, switch entire condensates on or off, reshape their composition, alter their viscosity, or harden them into less dynamic states without synthesizing new proteins—a degree of regulatory control that conventional signaling pathways cannot match.

Cancer exploits this control system in several ways, and the review systematically catalogues them. Mutations can add, remove, or charge-flip residues within disordered regions, shifting the phase boundary so that droplets form at concentrations where healthy cells never condense. Chromosomal translocations generate fusion proteins that stitch together a DNA-binding domain with a prion-like disordered domain, a combination notorious for driving condensate formation at oncogenic loci. Altered post-translational modification patterns, changes in RNA abundance, shifts in metabolic state, and the crowded, hypoxic, acidic environment of a tumor can all push condensates past their saturation point. The unifying theme, according to the authors, is that tumor cells do not need to invent new molecular machines; they can repurpose an existing physical mechanism of cellular organization and tilt it toward growth, survival, and spread.

The functional consequences are evaluated across five major domains of cancer biology. The first is signaling and transcription. Phase separation offers a mechanistic explanation for how transcription factors, co-activators, and the RNA polymerase machinery concentrate at specific genomic loci to form transcriptional hubs, and how signaling receptors cluster at membranes to amplify weak extracellular signals. If a tumor amplifies or mutates the multivalent components of these hubs, the hubs can become hyper-condensed, locking oncogenic programs into a permanently active state. The second domain is genome maintenance, where condensates are implicated in the response to double-strand breaks, in heterochromatin organization, and in the sequestration of repair factors. Condensate dysregulation here can either blunt DNA repair, promoting mutation accumulation, or paradoxically protect tumor cells from genotoxic therapies by concentrating repair machinery at damage sites.

The third and fourth domains—metastasis with cellular plasticity and tumor immunity—illustrate how condensate physics reaches beyond the nucleus. The review discusses how phase-separated assemblies participate in the epithelial–mesenchymal transition, cytoskeletal remodeling, and extracellular vesicle biology that enable tumor cells to detach, survive in circulation, and colonize distant tissues. On the immunity side, condensates shape the antigen presentation machinery, the formation of immune synapses in T cells, the behavior of stress granules during interferon signaling, and the cGAS–cGAMP–STING-type innate sensing pathways that determine whether a tumor looks like a threat to the immune system. A condensate that sequesters double-stranded RNA or dampens interferon-stimulated gene expression can effectively switch off the molecular alarm bells that would otherwise recruit cytotoxic T cells and natural killer cells to the tumor.

The fifth domain, therapeutic resistance, ties these mechanisms to the clinic. The review evaluates evidence that condensate formation contributes to resistance against tyrosine kinase inhibitors, PARP inhibitors, and androgen receptor pathway inhibition, among other therapies. The proposed mechanisms include the physical sequestration of drugs within dense phases, the concentration of drug targets into compartments where inhibitor penetration is poor, the buffering of inhibited pathways by condensate-stored reserves of signaling molecules, and stress granule–mediated survival programs that keep cells alive long enough to evolve durable resistance. Because these are physical, population-level phenomena rather than single gene mutations, they may explain forms of resistance that genomic sequencing alone cannot predict—adding a spatial and material dimension to the pharmacology of cancer treatment.

Perhaps the most forward-looking portion of the review concerns condensate-directed therapeutic strategies, which the authors assess explicitly according to the strength of their experimental and clinical evidence. Several classes of approach are now in play. Small molecules that partition into specific condensates can disrupt or remodel them; some such molecules have already demonstrated that selective condensate modulation is chemically achievable. Proteolysis-targeting chimeras, or PROTACs, can be designed to degrade the scaffold proteins or IDRs around which oncogenic condensates assemble. Oligonucleotide therapeutics can target the RNAs that nucleate pathological droplets. Nanoparticle platforms, including engineered particles designed to home in on and perturb specific condensates, represent a delivery-oriented strategy. The authors’ verdict, however, is deliberately cautious: the overwhelming majority of this work remains preclinical. Demonstrating that a compound dissolves a droplet in a test tube, or even in a cell line, is a long way from showing that it shrinks tumors in patients without dissolving the healthy condensates that normal cells depend on.

That caveat reflects the central challenge the review identifies for the field: specificity and validation. Cells are full of condensates that perform essential functions in nucleolar assembly, ribosome biogenesis, RNA processing, and stress adaptation, so a broadly acting condensate disruptor risks toxicity through collateral damage. Experimental validation remains difficult because phase separation in living cells is hard to prove unambiguously; methods such as live-cell imaging of fusion events, fluorescence recovery measurements, optogenetic control of multivalency, and proximity labeling are powerful but each carries its own artifacts. The authors also flag the conceptual danger of overextension, noting that the umbrella term biomolecular condensation covers a broader range of mechanisms and material states than LLPS proper, and that blurring the distinction has led the literature into claims that later scrutiny could not support. Their framework asks researchers to state which process they are actually observing and to apply matching criteria.

What emerges from the review is both a warning and a promise. The warning is that the condensate-cancer literature contains a mixture of rigorously validated LLPS mechanisms and incompletely characterized assemblies, and that therapeutic enthusiasm should be calibrated accordingly. The promise is that a genuine physical principle underlies a strikingly wide range of malignant behaviors—from oncogenic transcription to immune evasion to drug resistance—and that principle, unlike a mutation, is in principle reversible by changing the chemical environment of the cell. If the field can agree on how to prove that a droplet is a droplet, and if chemistry can deliver molecules that reshape only the condensates that matter, the energy stored in a decade of condensate biology may yet translate into the next generation of cancer therapeutics. For now, as the authors conclude, the potential remains predominantly preclinical, and the framework they propose is intended to make sure that the path from droplet to drug is followed with the same rigor that the physics itself demands.

Subject of Research: The role of liquid–liquid phase separation and biomolecular condensates in cancer mechanisms and therapy

Article Title: Liquid–liquid phase separation in cancer: mechanisms, biological functions, and therapeutic perspectives

Article References: Tang, P., Li, Y., Huang, C., Xiong, Y., Li, Y., Zhang, T., & Zhang, C. (2026). Liquid–liquid phase separation in cancer: mechanisms, biological functions, and therapeutic perspectives. Molecular Cancer. https://doi.org/10.1186/s12943-026-02798-0

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02798-0

Keywords: liquid–liquid phase separation, biomolecular condensates, cancer biology, intrinsically disordered regions, therapeutic resistance, transcriptional condensates, tumor immunity, metastasis, PROTACs, drug discovery, Molecular Cancer, condensate dysregulation

The EVA1 family has been attracting growing attention in recent years, although most of the spotlight has fallen on its siblings. EVA1A has been implicated in autophagy and cell death pathways and has been described as a prognostic biomarker in glioma and hepatocellular carcinoma, while EVA1C has been linked to immune infiltration in low-grade gliomas. EVA1B, by contrast, has remained comparatively obscure, with only a handful of studies hinting at oncogenic roles in colorectal cancer and esophageal squamous carcinoma. The new work is among the first to examine the protein systematically in lung cancer, combining large-scale bioinformatic analysis with hands-on experiments in human tissue samples, cultured cell lines, and animal models.

The investigation began in silico. By mining publicly available genomic datasets, the researchers found that EVA1B and LRG1 display subtype-specific expression patterns across NSCLC, differing between lung adenocarcinoma and squamous cell carcinoma. Crucially, the computational analysis suggested that the two molecules are not merely co-expressed by coincidence but may be functionally connected, a hypothesis that shaped the entire experimental program that followed. This kind of integrative transcriptomic approach has become a standard starting point for biomarker discovery, but the team went well beyond correlation, seeking physical and functional evidence in biological systems.

The first line of experimental evidence came from paired clinical samples obtained from patients at Fujian Cancer Hospital, work that was approved by the institution’s ethics committee with written informed consent from all participants. Using immunohistochemistry and Western blot analysis, the researchers compared tumor tissue with matched paracancerous tissue taken from the same patients. The results were unambiguous: EVA1B protein levels were consistently higher in the tumor specimens. The pattern was mirrored in cell culture, where two NSCLC cell lines, A549 and H1299, both expressed more EVA1B than BEAS-2B, an immortalized but non-malignant bronchial epithelial cell line used as a normal reference. Together, these findings established that EVA1B overexpression is a reproducible feature of NSCLC cells rather than an artifact of any single model system.

With overexpression confirmed, the researchers asked what happens when EVA1B is removed. Using knockdown techniques to suppress the protein in the A549 and H1299 cells, they ran a battery of functional assays designed to probe the hallmarks of malignancy. Proliferation, measured with CCK-8 assays, slowed markedly. Migration, assessed with wound-healing experiments, and invasion, measured with Transwell chambers, were both significantly impaired. In other words, cells stripped of EVA1B became less able to multiply, less able to move, and less able to chew their way through surrounding tissue, the three capabilities that together make a cancer dangerous.

The molecular signature behind these behavioral changes pointed to a well-known process called the epithelial–mesenchymal transition, or EMT, and its malignant cousin, the EMT-like phenotype. During EMT, epithelial cancer cells shed their adhesive, stationary identity and acquire the motile, invasive character of mesenchymal cells, a transformation that is widely regarded as a critical step in metastasis. When EVA1B was knocked down, the cells showed increased expression of E-cadherin, the epithelial marker that keeps cells glued together, and decreased expression of N-cadherin and Vimentin, two classic mesenchymal markers. Levels of matrix metalloproteinase 11, an enzyme that helps degrade the extracellular matrix and clear a path for invading cells, also fell. The coordinated shift in this marker panel indicates that EVA1B helps maintain the invasive, EMT-like state of NSCLC cells.

Cell culture can only say so much, so the team turned to animal models. In xenograft experiments, in which human cancer cells are implanted into immunocompromised mice, tumors with EVA1B knocked down grew significantly more slowly than controls. More strikingly, in a lung metastasis model, silencing EVA1B reduced the metastatic burden in the animals’ lungs, providing direct in vivo evidence that the protein contributes to the spread of disease, not just to growth of the primary tumor. These experiments, approved under the hospital’s animal ethics protocols, bring the findings closer to physiological relevance and strengthen the case that EVA1B is a genuine driver of NSCLC aggressiveness rather than a passive passenger.

The mechanistic heart of the study lies in its connection to LRG1, a secreted glycoprotein whose name reflects a leucine-rich repeat structure and whose levels have long been monitored as an inflammatory marker in clinical blood tests. In recent years, LRG1 has been recast as an active participant in disease, particularly in pathological blood vessel formation and in tumor biology. Previous work by other groups has shown that LRG1 derived from NSCLC cells can be packaged into exosomes and promote angiogenesis through transforming growth factor beta signaling, and that exosomal LRG1 can drive NSCLC proliferation and metastasis by binding the extracellular matrix protein fibronectin. The Fujian team’s bioinformatic analysis had flagged a functional association between EVA1B and LRG1, and co-immunoprecipitation experiments provided supporting evidence: EVA1B and LRG1 were found together in the same immunoprecipitated protein complex, suggesting that the two molecules associate within cells or in closely associated molecular assemblies. The authors are careful in their language, describing an LRG1-associated mechanism rather than claiming a fully defined direct interaction, an appropriate degree of caution given that co-immunoprecipitation detects co-complex membership and does not by itself prove direct physical binding between two purified proteins.

Even with that caveat, the convergence of evidence is compelling. EVA1B is overexpressed in patient tumors and cancer cell lines; removing it suppresses proliferation, migration, invasion, EMT-like marker switching, xenograft growth, and metastatic colonization; and the protein appears to operate in concert with LRG1, a molecule already implicated in NSCLC progression through independent lines of research. If future work confirms and elaborates the EVA1B–LRG1 axis, it could open several therapeutic avenues. LRG1 is a secreted protein, and secreted targets are generally more druggable than intracellular ones, with antibody-based approaches already being explored against LRG1 in ocular disease and cancer settings. Alternatively, EVA1B itself, or the downstream EMT programs it sustains, could serve as a biomarker to identify patients at high risk of metastasis, or as a target for combination strategies alongside existing EGFR inhibitors and immunotherapies, both of which face well-documented resistance problems in NSCLC.

For now, the study stands as a textbook example of how modern cancer biology progresses from computational hint to clinical sample to mechanistic model. It also adds a new branch to the growing tree of EVA1 family research, positioning EVA1B alongside its better-known relatives as a molecule worth watching. Lung cancer kills roughly 1.8 million people each year, and every newly validated node in its signaling network represents another potential vulnerability. The Fujian team’s work, supported by the Natural Science Foundation of Fujian, suggests that a once-overlooked protein and an inflammation-associated glycoprotein may together form one such node, and that dismantling it could help deprive NSCLC of its migratory edge.

Subject of Research: The role of the EVA1B protein and its association with LRG1 in driving non-small cell lung cancer progression and metastasis.

Article Title: EVA1B promotes non-small cell lung cancer progression through an LRG1-associated mechanism

Article References: Huang, Z., Wang, H., Jiang, K., & Zhuang, W. (2026). EVA1B promotes non-small cell lung cancer progression through an LRG1-associated mechanism. 3 Biotech, 16(10), Article 444. https://doi.org/10.1007/s13205-026-05034-0

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05034-0

Keywords: non-small cell lung cancer, EVA1B, LRG1, tumor progression, metastasis, EMT-like phenotype, epithelial-mesenchymal transition, biomarker, xenograft model, co-immunoprecipitation, cancer biology, A549 cells

The research team, led by investigators at Iuliu Hațieganu University of Medicine and Pharmacy, tested eight widely used anaesthetic compounds—noradrenaline, lidocaine, rocuronium bromide, suxamethonium chloride, ropivacaine, fentanyl, ketamine and propofol—against a panel of five human cancer cell lines and one normal cell line. The tumour models included lung adenocarcinoma (A549), colorectal carcinoma (HCT116), hepatocellular carcinoma (HUH7), triple-negative breast cancer (MDA-MB-231) and cutaneous melanoma (SK-MEL-28), each genetically characterised for key mutations in p53, KRAS and BRAF. Normal human fibroblasts served as a healthy comparator.

The first and most striking result was the sheer heterogeneity of response. Using the MTT metabolic assay after 48 hours of exposure, the researchers calculated IC50 values—the concentrations needed to halve cell viability—that varied enormously between drugs and between cell lines. Lidocaine was highly potent against the colon and liver cancer cells, yet barely affected the triple-negative breast cancer line. Rocuronium bromide showed no inhibitory effect on liver and breast cancer cells but was strikingly active against melanoma. Fentanyl, at the doses and exposure times tested, failed to reduce metabolic activity in any of the cell lines. Ketamine and propofol, both intravenous agents, inhibited growth across most tumour models, with colon cancer cells proving the most sensitive to ketamine at 337 micromolar.

Importantly, the normal fibroblasts were generally more resistant than the tumour cells. Only four of the eight compounds—noradrenaline, ropivacaine, ketamine and propofol—reached an inhibitory threshold in the healthy cells, and for ropivacaine, ketamine and propofol the required doses were higher than those needed to suppress the cancer lines. That therapeutic window, the authors note, is a prerequisite for any future clinical relevance, since an ideal perioperative agent should harm tumour cells without damaging surrounding healthy tissue.

Beyond simple viability, the team probed whether the drugs could blunt two hallmarks of aggressive cancer: migration and the capacity to seed new colonies. In wound-healing assays, none of the compounds stimulated migration, and several strongly inhibited it, though in a strikingly cell-line-dependent fashion. Suxamethonium chloride nearly halted the movement of lung cancer cells, allowing only 23 percent wound closure, while lidocaine and ketamine were the most effective suppressors of breast cancer cell migration. Melanoma cells proved remarkably stubborn, with rocuronium bromide the only agent to completely block their movement. Colony formation assays told a similar story of selective vulnerability: propofol and ketamine inhibited colony formation in every tumour line tested, whereas noradrenaline was the sole compound able to suppress melanoma colonies.

Confocal fluorescence microscopy revealed the structural chaos the drugs inflict inside cells. Treated tumour cells displayed mitochondrial fragmentation and depolarisation, nuclear condensation, collapse of the F-actin cytoskeleton, cell swelling and the formation of tunnelling nanotubes—thin membrane bridges that emerge under cellular stress. The pattern of damage differed by drug and by tumour type. Lidocaine and noradrenaline wrecked the mitochondrial networks and actin filaments of lung cancer cells, while propofol triggered extensive mitochondrial fragmentation in liver cancer cells. Because cytoskeletal integrity and mitochondrial function underpin both motility and survival, these structural disruptions likely explain the functional losses measured in the migration and colony assays.

Flow cytometry added a dynamic dimension. Several compounds, most notably ketamine and propofol, pushed cells into a quiescent G0/G1 arrest, effectively freezing them before DNA replication. In lung cancer cells, ketamine trapped nearly 85 percent of the population in G0/G1, compared with 70 percent in untreated controls. In breast cancer cells, propofol froze 70 percent of cells in the same phase. Apoptosis measurements using PoPRO1 and 7-AAD staining showed that rocuronium bromide drove almost half of the triple-negative breast cancer population into late apoptosis within 24 hours, while colon cancer cells resisted all compounds, with no agent inducing more than 20 percent cell death. Melanoma cells were highly sensitive to noradrenaline and rocuronium, each triggering roughly 35 percent apoptosis.

At the molecular level, the picture grew more nuanced. Gene expression analysis of caspases 3, 8 and 9—the proteases that execute apoptosis—alongside the stress regulator NRF2, the inflammatory transcription factor NF-κB and the cyclin-dependent genes controlling cell cycle progression, revealed cell-specific signatures. In colon cancer cells, ropivacaine, fentanyl and ketamine significantly upregulated caspase 8, while rocuronium, suxamethonium and ropivacaine suppressed NRF2, hinting at a collapse of redox homeostasis. Liver cancer cells responded with a significant upregulation of CDK1-cyclin B and downregulation of CDK4-cyclin D, a pattern consistent with a compensatory attempt to escape a G1 blockade. Western blotting for cleaved PARP and cleaved caspase 3 confirmed that some drug–cell combinations, particularly lidocaine and ketamine in liver cancer cells, activate the classical caspase-dependent apoptosis pathway, whereas melanoma cells showed no detectable PARP or caspase 3 cleavage at all, suggesting they rely on entirely different death mechanisms.

The authors are careful to place these results in context. The experimental concentrations deliberately extended far beyond those achievable in patients, in order to characterise pharmacological activity and determine IC50 values. For propofol, lidocaine, ketamine, ropivacaine and fentanyl, clinically achievable perioperative plasma concentrations do fall within the tested ranges, but most experimental doses exceeded routine clinical exposure, and effects seen only at supraphysiological concentrations may not translate to the operating room. Succinylcholine, with a plasma half-life under one minute, poses particular interpretive challenges when compared against 48-hour in vitro exposures. The two-dimensional monolayer cultures also lack the stromal architecture, immune cells and extracellular matrix of real tumours, and perioperative neuroendocrine stress and transient immunosuppression cannot be recapitulated in a dish.

Nevertheless, the study’s central message is cautiously encouraging: across every assay, no anaesthetic compound stimulated tumour cell proliferation, and most acted as growth inhibitors. The pronounced heterogeneity—colon cancer cells resisting cell death while breast cancer cells succumbed to rocuronium, for instance—supports the authors’ vision of a personalised anaesthetic strategy, in which the drugs chosen for cancer surgery might one day be matched to the molecular profile of the tumour being removed. With randomised clinical trials to date showing largely neutral effects of anaesthetic technique on long-term oncological outcomes, the researchers argue that rigorous translational work, integrating pharmacokinetic data with clinically relevant exposure models and progressing through in vivo studies, is essential before laboratory observations can be turned into perioperative practice. For now, the operating room remains a place where the drugs that quiet the nervous system may also, quietly, influence the fate of lingering cancer cells.

Subject of Research: In vitro effects of commonly used anaesthetic compounds on the proliferation, migration, cell cycle and gene expression of solid tumour cell lines

Article Title: In Vitro Effects of Anaesthetic Compounds on a Panel of Solid Tumour Cell Lines—An Exploratory Study

Article References: Grajdieru, O., Sabo, A. C., Tigu, A. B., Ivancuta, A., Moldovan, C. S., Uhl, A., Ungurenasu, M. C., Balmez, A.-I., Moisescu, A., Pîrv, S., Nistor, M., Muresan, X.-M., Cenariu, D., Tomuleasa, C., & Constantinescu, C. (2026). In Vitro Effects of Anaesthetic Compounds on a Panel of Solid Tumour Cell Lines—An Exploratory Study. Journal of Cellular and Molecular Medicine, 30(18), Article e71307. https://doi.org/10.1111/jcmm.71307

Image Credits: AI Generated

DOI: 10.1111/jcmm.71307

Keywords: anaesthetic drugs, cancer cell lines, propofol, ketamine, lidocaine, tumour recurrence, perioperative medicine, apoptosis, cell cycle arrest, triple-negative breast cancer, in vitro study, cancer biology